Brand name and specialty drugs can be expensive. Almost all employment-based health insurance includes levels of copays on drugs and in some cases a deductible may be applicable as well. Concern has been raised about whether this cost-sharing may inhibit appropriate use of medications. A CDC brief based on 2013 survey data explores how adults deal with this issue. (CDC Brief) About 18% of drug costs in 2012 were paid out-of-pocket. According to the survey, 7.8% of adults over age 18 did not take a drug as prescribed to save money. This might include not filling the prescription or skipping doses. This tactic was less prevalent among Medicare eligible adults, only 4.4% of whom attempted to cut costs by not using the medication as recommended. Another 14.7% of all adults said they had asked their doctor for a lower-cost medicine, and here 17% of Medicare beneficiaries had done so. 1.6% purchased drugs from another country to limit their spending and 4.8% used an alternative therapy. As might be expected, the uninsured had higher rates of using these approaches to avoid spending. Medicaid patients, who often have no or very low copays, had lower rates, but still higher than the privately insured population. Poorer adults in general had the highest rates of not taking medication as prescribed and there was a clear association at all income levels, with higher income leading to more compliance with prescriptions. The survey findings indicate that for a substantial minority of the population, drug costs are a sufficient concern that they may be non-compliant with therapy. In many cases, this could lead to poorer health outcomes.
By Kevin RocheFebruary 12, 2015Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 21, 2023
Minnesota’s New Energy Insanity, Part 7
Minnesota is a particularly poor place to rely on solar power, but other states aren't…
March 21, 2023
A Quick SVB Follow-up
As I suspected, the SVB saga is primarily one of regulatory malfeasance, coupled with political…
March 19, 2023
Tom Frieden Speaks in the WSJ
A public health expert writes an article for the WSJ which amply demonstrates why Americans…